Targeted Drugs Lift 5-Year Cancer Survival to 70% as 18 Million Americans Live After Diagnosis
Updated
Updated · Reuters · Jun 3
Targeted Drugs Lift 5-Year Cancer Survival to 70% as 18 Million Americans Live After Diagnosis
3 articles · Updated · Reuters · Jun 3
Summary
Seven in 10 U.S. cancer patients now survive at least five years, a record rate that has climbed from less than half in the 1970s as targeted therapies spread.
Genetic profiling is driving that shift: trials that enroll patients by specific mutations have nearly doubled success rates, and experts say full genomic testing is becoming essential to match tumors with drugs.
ASCO data presented in Chicago showed cancer deaths among people aged 15 to 49 have fallen 25% since 1990, alongside new trial results for pancreas, skin and blood cancers.
Less than a third of recently approved cancer drugs were proven to extend life spans, underscoring why doctors still rely on repeated biopsies and mutation testing to find treatments that keep patients living with cancer longer.
The American Cancer Society estimates 18 million Americans who have ever had cancer are alive today, and researchers expect survival to keep improving even as cancer remains the No. 2 cause of death.
As miracle cancer drugs extend life, who can actually afford the price of survival?
With treatments tailored to a tumor's DNA, what hope is left for those without the 'right' mutation?
What happens when a patient's cancer learns to outsmart these new precision therapies?
U.S. Cancer Survival Rates 2025: Advances, Challenges, and Future Innovations
Overview
Cancer survival in the U.S. has seen significant progress as of January 2025, thanks to decades of advancements in prevention, early detection, and treatment. Research and clinical care have led to a sustained decline in cancer mortality rates, with an estimated 4.8 million deaths averted since 1991. This progress has resulted in a growing population of cancer survivors who benefit from more effective interventions. Notably, breast cancer outcomes have improved dramatically, with major advances in awareness, detection, and treatment strategies leading to an overall five-year survival rate of about 90 percent.